

Bertram L Kasiske

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9483886/publications.pdf>

Version: 2024-02-01

96
papers

10,306
citations

61984

43
h-index

37204

96
g-index

101
all docs

101
docs citations

101
times ranked

11872
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients. JAMA - Journal of the American Medical Association, 2011, 306, 1891.	7.4	1,176
2	Cancer after Kidney Transplantation in the United States. American Journal of Transplantation, 2004, 4, 905-913.	4.7	924
3	KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, 2010, 77, 299-311.	5.2	675
4	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	13.7	662
5	Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1735-1743.	6.1	440
6	Hypertension after kidney transplantation. American Journal of Kidney Diseases, 2004, 43, 1071-1081.	1.9	356
7	A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1910-1917.	6.1	356
8	New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. Journal of the American Society of Nephrology: JASN, 2014, 25, 1842-1848.	6.1	338
9	A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. American Journal of Kidney Diseases, 2013, 62, 577-586.	1.9	323
10	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation, 2017, 101, S7-S105.	1.0	308
11	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	1.0	306
12	An economic assessment of contemporary kidney transplant practice. American Journal of Transplantation, 2018, 18, 1168-1176.	4.7	250
13	Scientific Registry of Transplant Recipients: Collecting, analyzing, and reporting data on transplantation in the United States. Transplantation Reviews, 2013, 27, 50-56.	2.9	246
14	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
15	Cigarette Smoking in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2000, 11, 753-759.	6.1	182
16	Acute Myocardial Infarction and Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2006, 17, 900-907.	6.1	165
17	Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB Journal, 1988, 2, 2339-2347.	0.5	135
18	The evaluation of renal transplantation candidates: clinical practice guidelines. American Journal of Transplantation, 2001, 1 Suppl 2, 3-95.	4.7	130

#	ARTICLE	IF	CITATIONS
19	Melanoma Risk and Survival among Organ Transplant Recipients. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2657-2665.	0.7	108
20	Long-Term Deterioration of Kidney Allograft Function. <i>American Journal of Transplantation</i> , 2005, 5, 1405-1414.	4.7	107
21	Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. <i>Hepatology</i> , 2015, 61, 1643-1650.	7.3	107
22	The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 562-571.	4.5	85
23	Matching Older Kidneys with Older Patients Does Not Improve Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1067-1072.	6.1	80
24	A Simple Tool to Predict Outcomes After Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 56, 947-960.	1.9	75
25	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 708-714.	1.0	73
26	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	5.2	72
27	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , 2015, 87, 527-534.	5.2	70
28	A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. <i>American Journal of Kidney Diseases</i> , 2002, 39, 762-768.	1.9	65
29	Long-term medical risks to the living kidney donor. <i>Nature Reviews Nephrology</i> , 2015, 11, 411-419.	9.6	63
30	Survival implications of opioid use before and after liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 305-314.	2.4	63
31	Polycystic Kidney Disease and Cancer after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2335-2341.	6.1	59
32	Organ distribution without geographic boundaries: A possible framework for organ allocation. <i>American Journal of Transplantation</i> , 2018, 18, 2635-2640.	4.7	56
33	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1894-1905.	0.8	54
34	Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 505-511.	4.5	49
35	Risk-Stratified Screening for Ischemic Heart Disease in Kidney Transplant Candidates. <i>Transplantation</i> , 2005, 80, 815-820.	1.0	48
36	A New Panel-Estimated GFR, Including \hat{I}^2 -Microglobulin and \hat{I}^2 -Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021, 77, 673-683.e1.	1.9	47

#	ARTICLE	IF	CITATIONS
37	Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. <i>Transplant International</i> , 2018, 31, 198-211.	1.6	46
38	Gout After Living Kidney Donation: A Matched Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 925-932.	1.9	45
39	Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. <i>American Journal of Transplantation</i> , 2019, 19, 1356-1370.	4.7	41
40	Late graft failure after kidney transplantation as the consequence of late versus early events. <i>American Journal of Transplantation</i> , 2018, 18, 1158-1167.	4.7	39
41	Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. <i>Transplantation</i> , 2019, 103, 2373-2382.	1.0	36
42	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , 2020, 98, 168-175.	5.2	34
43	Ischemic heart disease after renal transplantation. <i>Kidney International</i> , 2002, 61, 356-369.	5.2	32
44	Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review. <i>Clinical Transplantation</i> , 2021, 35, e14320.	1.6	32
45	The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-stage Liver Disease Scores and Exception Statuses. <i>Liver Transplantation</i> , 2022, 28, 363-375.	2.4	31
46	Design Considerations and Feasibility for a Clinical Trial to Examine Coronary Screening Before Kidney Transplantation (COST). <i>American Journal of Kidney Diseases</i> , 2011, 57, 908-916.	1.9	30
47	Mortality among solid organ waitlist candidates during COVID-19 in the United States. <i>American Journal of Transplantation</i> , 2021, 21, 2262-2268.	4.7	24
48	Temporal trends, center-level variation, and the impact of prevalent state obesity rates on acceptance of obese living kidney donors. <i>American Journal of Transplantation</i> , 2018, 18, 642-649.	4.7	23
49	Continuous distribution as an organ allocation framework. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 115-121.	1.6	23
50	Kidney Disease: Improving Global Outcomes--an update. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 763-769.	0.7	20
51	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. <i>Kidney International</i> , 2016, 90, 861-868.	5.2	20
52	Lifetime benefits of early detection and treatment of diabetic kidney disease. <i>PLoS ONE</i> , 2019, 14, e0217487.	2.5	20
53	Long-term follow-up of the DeKAF cross-sectional cohort study. <i>American Journal of Transplantation</i> , 2019, 19, 1432-1443.	4.7	20
54	What patients and members of their support networks ask about transplant program data. <i>Clinical Transplantation</i> , 2017, 31, e13125.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Application of the 2017 KDIGO Guideline for the Evaluation and Care of Living Kidney Donors to Clinical Practice. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 896-905.	4.5	19
56	Transplant recipients are vulnerable to coverage denial under Medicare Part D. <i>American Journal of Transplantation</i> , 2018, 18, 1502-1509.	4.7	18
57	The economic burden of kidney graft failure in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 1323-1333.	4.7	18
58	Inflammation in areas of fibrosis: The DeKAF prospective cohort. <i>American Journal of Transplantation</i> , 2020, 20, 2509-2521.	4.7	18
59	The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. <i>Kidney International</i> , 2014, 85, 404-415.	5.2	17
60	Offer acceptance practices and geographic variability in allocation model for end-stage liver disease at transplant. <i>Liver Transplantation</i> , 2018, 24, 478-487.	2.4	17
61	Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis. <i>Transplantation Direct</i> , 2018, 4, e364.	1.6	16
62	iFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts. <i>American Journal of Transplantation</i> , 2021, 21, 1866-1877.	4.7	16
63	Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry. <i>Transplantation Direct</i> , 2021, 7, e689.	1.6	16
64	Impact of Functional Status on Outcomes of Simultaneous Pancreas-kidney Transplantation: Risks and Opportunities for Patient Benefit. <i>Transplantation Direct</i> , 2020, 6, e599.	1.6	15
65	Closing the gap between evidence and practice in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 114-121.	14.2	14
66	Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. <i>American Journal of Kidney Diseases</i> , 2014, 63, 753-760.	1.9	13
67	Outcomes After Living Kidney Donation: What We Still Need to Know—and Why. <i>American Journal of Kidney Diseases</i> , 2014, 64, 335-337.	1.9	13
68	Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee. <i>Kidney International</i> , 2016, 89, 753-760.	5.2	13
69	Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. <i>Clinical Transplantation</i> , 2019, 33, e13696.	1.6	13
70	Procurement Biopsies in Kidney Transplantation: More Information May Not Lead to Better Decisions. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1835-1837.	6.1	13
71	Antidepressant medication use before and after kidney transplant: implications for outcomes - a retrospective study. <i>Transplant International</i> , 2018, 31, 20-31.	1.6	12
72	Prescription opioid use before and after heart transplant: Associations with posttransplant outcomes. <i>American Journal of Transplantation</i> , 2019, 19, 3405-3414.	4.7	12

#	ARTICLE	IF	CITATIONS
73	Impact of increased time at the highest urgency category on heart transplant outcomes for candidates with ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 326-334.	0.6	10
74	The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset. <i>American Journal of Kidney Diseases</i> , 2013, 61, 371-374.	1.9	8
75	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 130-137.	14.2	8
76	Tool to Aid Patients in Selecting a Liver Transplant Center. <i>Liver Transplantation</i> , 2020, 26, 337-348.	2.4	8
77	Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 513-524.	0.6	7
78	A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-16.	0.5	6
79	Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. <i>Kidney International</i> , 2016, 89, 1189-1191.	5.2	6
80	Outcome implications of benzodiazepine and opioid co-prescription in kidney transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14005.	1.6	6
81	Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection "The long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14337.	1.6	6
82	Outcomes of living liver donor candidate evaluations in the Living Donor Collective pilot registry. <i>Clinical Transplantation</i> , 2021, 35, e14394.	1.6	6
83	Cancer risk in living kidney donors. <i>American Journal of Transplantation</i> , 2022, 22, 2006-2015.	4.7	6
84	Prescription patterns of opioids and non-steroidal anti-inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records. <i>Clinical Transplantation</i> , 2020, 34, e14000.	1.6	4
85	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective. <i>American Journal of Kidney Diseases</i> , 2007, 50, 354-357.	1.9	3
86	Evidence and Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2012, 59, 492-494.	1.9	3
87	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension After Kidney Transplantation: Analysis of Linked US Registry and Medicare Billing Claims. <i>Transplantation</i> , 2022, 106, 666-675.	1.0	3
88	Five Years With the American Journal of Kidney Diseases on the Road to Evidence-Based Medicine. <i>American Journal of Kidney Diseases</i> , 2022, 79, 1-2.	1.9	3
89	Economic impacts of alternative kidney transplant immunosuppression: A national cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13813.	1.6	2
90	Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13803.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Associations of Lack of Insurance and Other Sociodemographic Traits With Follow-up After Living Kidney Donation. American Journal of Kidney Diseases, 2022, 80, 683-685.	1.9	2
92	Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference. Clinical Transplantation, 0, , .	1.6	2
93	The kidney and lipids: preface. Clinical and Experimental Nephrology, 2014, 18, 180-184.	1.6	0
94	The Authors Reply:. Kidney International, 2015, 87, 863-864.	5.2	0
95	The Authors Reply. Kidney International, 2016, 90, 708.	5.2	0
96	Transplant program evaluations in the middle of the <scp>COVID</scp> â€“19 pandemic. American Journal of Transplantation, 0, , .	4.7	0